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esponsibility of InstAbstract The Keap1–Nrf2–ARE pathway is an important antioxidant defense mechanism that protects
cells from oxidative stress and the Keap1–Nrf2 protein–protein interaction (PPI) has become an
important drug target to upregulate the expression of ARE-controlled cytoprotective oxidative stress
response enzymes in the development of therapeutic and preventive agents for a number of diseases and
conditions. However, most known Nrf2 activators/ARE inducers are indirect inhibitors of Keap1–Nrf2
PPI and they are electrophilic species that act by modifying the sulfhydryl groups of Keap1's cysteine
residues. The electrophilicity of these indirect inhibitors may cause "off-target" side effects by reacting
with cysteine residues of other important cellular proteins. Efforts have recently been focused on the
development of direct inhibitors of Keap1–Nrf2 PPI. This article reviews these recent research efforts
including the development of high throughput screening assays, the discovery of peptide and small
molecule direct inhibitors, and the biophysical characterization of the binding of these inhibitors to the
target Keap1 Kelch domain protein. These non-covalent direct inhibitors of Keap1–Nrf2 PPI could8
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Dhulﬁqar Ali Abed et al.286potentially be developed into effective therapeutic or preventive agents for a variety of diseases and
conditions.
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Redox reactions are a vital component of many natural physiolo-
gical processes, and as a result, the human body is constantly
exposed to numerous oxidative and electrophilic chemicals. The
imbalance between biochemical processes leading to the produc-
tion of oxidative and electrophilic species and those responsible
for the removal of these chemicals is referred to as oxidative
stress1. Oxidative stress can be caused by excess reactive oxygen
species (ROS) and reactive nitrogen species (RNS) generated from
both exogenous and endogenous sources. Exogenous oxidative
sources include carcinogenic chemicals, environmental carcino-
gens, and radiation. Endogenous oxidative sources include che-
micals involved in intracellular processes such as cellular
signaling, metabolic processes, and inﬂammation that produce
oxidative conditions within the body1,2. ROS include superoxide
ðO2 UÞ, hydrogen peroxide (H2O2), hydroxyl radical (OH  ), and
singlet oxygen (1O2) and they can oxidize DNA, leading to DNA
damage. RNS include peroxynitrate ðONO2 Þ and nitric oxide
(NO), which are also DNA oxidants1,2. ROS and RNS are
generated in the body as the result of natural physiological
processes such as aerobic respiration in mitochondria and during
inﬂammatory responses that protect our body from foreign
pathogens and, in some cases, serve as signaling molecules.
Sustained oxidative damage is associated with inﬂammation, aging
and a number of diseases including cancer, diabetes, atherosclero-
sis, hypertension, cystic ﬁbrosis, Parkinson's and Alzheimer's
diseases2,3. Since sustained oxidative stress conditions can cause
damage to DNA and vital cellular structures, the human body has
developed antioxidative and cytoprotective mechanisms against
various kinds of oxidative stress4,5.
The antioxidant defense system is the major protective mecha-
nism used by cells to defend against and neutralize the damaging
effects of oxidants and electrophiles4,5. As shown in Fig. 1, the
antioxidant defense system can involve the direct reduction of the
reactive oxygen or nitrogen species by low molecular weight
compounds from endogenous sources or our diet. These antioxi-
dants are redox-active, short-lived, and consumed or modiﬁed
during the process and therefore they need to be replenished or
regenerated to offer further protection. Examples of these anti-
oxidants include glutathione, ascorbate (vitamin C), tocopherols
(vitamin E), lipoid acid, vitamin K, and ubiquinol, and other
polyphenolic compounds4. In addition, there are various antiox-
idant enzymes that are involved in the more effective, catalytic
detoxiﬁcation of reactive oxygen or nitrogen species. These
enzymes include NAD(P)H, NAD(P)H quinone oxidoreductase I
(NQO1), superoxide dismutase (SOD), glutathione S-transferase
(GST), glutathione peroxidase (GPx), heme-oxygenase-1 (HO-1),
glutamate-cysteine ligase (GCL), catalase, and thioredoxin
(TRX)4,6. These cytoprotective proteins have relatively long
half-lives, are not consumed in their antioxidant actions, and can
catalyze a wide variety of chemical detoxiﬁcation reactions; someof them are involved in regeneration of the small molecule
antioxidants4. Many of these antioxidant cytoprotective enzymes
are controlled by the same three-component transcription pathway:
the antioxidant response element (ARE), the nuclear factor
erythroid 2–related factor 2 (Nrf2), and the Kelch-like ECH-
associated protein 1 (Keap1)4,7.2. Components of the Keap1–Nrf2–ARE pathway
2.1. Antioxidant response element (ARE)
ARE, also known as the electrophile response element (EpRE), is a
cis-regulatory element or enhancer sequence, which is found in the
promoter region of numerous genes encoding detoxiﬁcation
enzymes and cytoprotective proteins8. The nucleotide sequence of
ARE has been investigated in numerous mutagenic analysis
studies9–11. The exact ARE sequence varies between genes; how-
ever, the typical functionally active ARE is a 16 nucleotide sequence
of 50-TA/CAnn
A/GTGA
C/GTGA
C/GnnnGC
A/G-30, where n is any
nucleotide7,11. Under conditions of oxidative stress, stabilized Nrf2
translocates to the nucleus, where it forms a heterodimer with Maf,
and binds to the ARE sites, leading to the activation of downstream
target genes8,12,13. Bach1 (BTB and CNC homology 1) is a
transcriptional repressor of ARE. Under normal physiological
conditions, Bach1 forms a dimer with Maf protein, preventing
Nrf2 from binding to DNA. In response to ARE inducers, Bach1
undergoes rapid nuclear export and proteasomal degradation.2.2. Nuclear factor erythroid 2–related factor 2 (Nrf2)
Nrf2 is a transcription factor which is essential for maintaining cellular
homeostasis14. It is a 66-kDa cap ‘n’ collar (CNC) protein with a basic
leucine zipper (bZip) DNA binding motif that is characteristic of NF-
E215. Nrf2 contains 6 highly conserved domains named Nrf2-ECH
homology domains (Neh1-6, Fig. 2)16. The ﬁrst domain, Neh1
domain, corresponds to the bZip motif necessary for dimerization
with Maf and binding to DNA17. Additionally, the DNA binding
domain within Neh1 was found to have a nuclear localization
sequence (NLS, residues 494–511), which is necessary for the nuclear
localization of Nrf218. The highly conserved Neh2 domain lies at the
N-terminal region of the protein. It serves as a negative regulatory
domain in Nrf2 transcriptional activity. Neh2 contains DLG and
ETGE motifs which correspond to the two binding sites for the Keap1
Kelch domain that facilitate the formation of a complex composed of
one molecule of Nrf2 and two molecules of Keap119,20. The presence
of seven lysine residues within Neh2 allows for negative regulation of
Nrf2 transcriptional activity via proteasome-mediated Nrf2 degrada-
tion21. The presence of a serine residue (Ser40) in the Neh2 domain is
essential for release of Nrf2 from Keap1. Phosphorylation at Ser40 is
required for Nrf2 to dissociate from Keap1 and thus avoid Keap1-
Figure 2 The organization and domain structure of Nrf2.
Figure 1 The antioxidant defense system employed by our body to defend against and neutralize the damaging effects of oxidative stress.
Reactive oxygen species (ROS) and reactive nitrogen species (RNS) are constantly produced by normal cellular processes and environmental
sources. Their damaging effects are mitigated through direction reduction by dietary or endogenous antioxidants or through the more efﬁcient
catalytic detoxiﬁcation by various antioxidant enzymes under the control of transcription factor Nrf2. Keap1 serves as an important redox sensor
involved in the feedback regulation of oxidative stress response.
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stabilization and accumulation in the nucleus14. The Neh3 domain
of Nrf2 is among members of the CNC bZIP transcription factors. It is
located at the C-terminus of the protein and is essential for the
transactivation of ARE gene by Nrf222. The Neh4 and Neh5 domains
are considered transactivation domains that cooperatively bind to
cAMP response element binding (CREB) protein (CBP), which has
been shown to be essential co-activator for many transcription factors.
Finally, Neh6 domain which is located in the middle of Nrf2 and has
been reported to be associated with redox-insensitive degradation of
the Nrf222,23.2.3. Kelch-like ECH-associated protein 1 (Keap1)
Keap1 is a 69.7-kD actin-binding protein composed of 625 amino
acid residues, 27 of which are cysteine residues24. As shown in
Fig. 3, Keap1 consists of ﬁve distinct domains: (i) the N-terminal
region (NTR), (ii) the broad complex, tramtrack and bric-a-brac
(BTB) domain, (iii) the intervening region (IVR), (iv) the double
glycine repeats (DGR) or Kelch domain, (v) and the C-terminal
region (CTR)25. The BTB domain is an evolutionary conserved
domain also found in actin-binding proteins and zinc ﬁngertranscription factors25. Keap1 forms a homodimer through
the BTB domain and dimerization is required for binding to
Nrf226. In addition, the BTB domain is also responsible for the
interaction between Keap1 and Cullin3-Rbx1 E3 ubiquitin ligase
(Cul3-E3-ligase)24,27. The cysteine rich IVR is sensitive to
oxidation and the nuclear export signal (NES) motif, and is
necessary for Keap1 activity26,28. In the IVR domain of Keap1,
four especially reactive cysteine residues have been identiﬁed:
Cys257, Cys273, Cys288 and Cys297. Cys273 and Cys288 are essential
for Keap1-dependent ubiquitination of Nrf2 and Keap1-mediated
repression of Nrf2 activity28,29. Both the BTB and (IVR) domains
were shown to be essential for Nrf2 degradation30. The Kelch
domain consists of six repeating Kelch motifs (KR1–KR6) that
form a six-bladed β-propeller structure31. The Kelch domain is
where Keap1 binds to the Neh2 domain of Nrf232.3. Mechanism and regulation of the Keap1–Nrf2–ARE
pathway
Keap1 functions as a master regulator of the Keap1–Nrf2–ARE
pathway by controlling the steady state level of Nrf2 based on
cellular redox conditions33. Under basal conditions, Nrf2 is bound
Figure 3 The organization and domain structure of Keap1.
Figure 4 The Keap1-Nrf-ARE pathway. In the "hinge" and "latch" mechanism of Nrf2 regulation, the high afﬁnity ETGE motif of Nrf2 initially
binds to Kelch domain of Keap1 and the lower afﬁnity afﬁnity DLG motif binds to the second Keap1 to close the conformation. Nrf2 is
polyubiquitinated at its Lys rich (7K) region and targeted for subsequent degradation by the 26S proteasome.
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proteasomal degradation by Cul3-E3-ligase, with a t1/2 of less than
20 min. The rapid turnover of Nrf2 prevents the unnecessary
expression of Nrf2 target genes34–37. Keap1 forms a homodimer
via its BTB domain. The Neh2 domain of Nrf2 contains two
binding motifs: the high afﬁnity ETGE and the low afﬁnity DLG
motifs36,38. The ETGE and DLG motifs each bind to a separate
Kelch domain in the Keap1 dimer. The binding of each motif to a
Kelch domain (“two-site substrate recognition”) is required for the
ubiquitination of Nrf2 that leads to its rapid degradation by 26S
proteasome under basal conditions. The ubiquitination of Nrf2
occurs at an α-helix with seven lysine residues located between the
binding motifs39. Under induced conditions, the Keap1–Nrf2–
Cul3 complex is disturbed. As a consequence, Nrf2 is stabilized
(t1/2 of up to 200 min) and can translocate to the nucleus. Two
mechanistic models have been proposed for Nrf2 stabilization: the
“Keap1-Cul3 dissociation model” and the “hinge and latch
model”37,40.
In the Keap1-Cul3 dissociation model, it is proposed that
inducers stabilize Nrf2 by dissociating the Keap1-Cul3 complex,
resulting in the inhibition of ubiquitination and stabilization of
Nrf237. Under induced conditions, covalent modiﬁcation of
cysteine residues in the BTB domain of Keap1 leads to a “steric
clash” between Keap1 and Cul339. This results in the dissociation
of the Keap1–Cul3 interaction and, therefore, disruption of Keap1-Cul3-E3-ligase activity39,41. Cys151 has been found to be necessary
to achieve this effect21,41. Substitution of serine for Cys151 in the
BTB domain renders Keap1 unable to dissociate from Nrf2 even in
the presence of oxidative stress. This suggests that Cys151
functions as a sensor for oxidants and electrophiles and plays a
crucial role in Nrf2 activation29,34,39,42–45. Other mechanisms for
Nrf2 stabilization in response to inducers have been proposed, but
will not be discussed here. These alternative mechanisms include
nucleocytoplasm shuttling of Keap1, ubiquitination of Keap1, and
Nrf2 as a direct sensor37.
In the “hinge and latch model” shown in Fig. 4, Nrf2-Keap1
contact is mediated by a strong binding interaction between the
ETGE motif and one Kelch domain of Keap1 (the “hinge”), and a
weaker binding interaction between the DLG motif and the other
Kelch domain of Keap1 (the “latch”)33,36. The high-afﬁnity ETGE
motif functions as a “hinge” by ﬁxing Nrf2 to Keap1. The low-
afﬁnity DLG motif functions as a “latch” by locking or unlocking
the position of Nrf2 depending on the redox state of the cell.
Under basal conditions, the DLG motif locks the Neh2 domain in
the correct position to enable the ubiquitination and degradation of
Nrf2 in proteasomes36,40,46. When under oxidative stress, cysteine
residues in Keap1 become oxidized and this modiﬁcation unlocks
the “latch”. Under these conditions, the orientation of Nrf2
prevents ubiquitination by the Keap1-Cul3 complex and this
process leads to Nrf2 stabilization33,40,46,47. As a result, Nrf2
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translocates to the nucleus, forms a heterodimer with Maf, binds to
ARE and therefore promotes the transcription of ARE-dependent
genes30,32,34,48.4. The Keap1–Nrf2–ARE pathway as a therapeutic target
Inﬂammation and oxidative stress play an essential role in the
pathogenesis of many human diseases and conditions49. Inﬂam-
mation in the body produces large amounts of ROS and RNS that
can induce oxidative damage to DNA and other cellular molecules
including membrane lipids and proteins25. The Keap1–Nrf2–ARE
pathway is a major defense mechanism used to counteract
oxidative stress. This pathway protects many organs and cells
and the pathway's protective role has been implicated in many
human disorders50, including cancer, neurological diseases, airway
disorders, cardiovascular diseases, diabetes, inﬂammatory bowel
disease (IBS), and autoimmune diseases. Regulation of the Nrf2–
ARE signaling has also been implicated in basic health, lifespan,
and aging50. The role of the Keap1–Nrf2–ARE pathway in
oxidative stress and age related diseases offers novel therapeutic
and pharmacologic opportunities as we reviewed previously7. This
section discusses brieﬂy the major diseases and conditions that
involve oxidative stress and the Keap1–Nrf2–ARE pathway and
that could potentially be treated by modulators of this pathway.
4.1. Cancer
ROS and oxidative stress are a hallmark of human cancer49. The
initiation of the formation of many tumors results from damage to
DNA by electrophilic carcinogen metabolites or by ROS. The
hypothesis that oxidative-stress induced lesions contribute to
carcinogenesis is supported by the increased susceptibility to
cancer observed in patients with a variety of chronic inﬂammatory
diseases including ulcerative colitis, viral hepatitis, prostatitis,
Helicobacter pylori infection, parasitic diseases, and many others.
In patients with inﬂammatory diseases such as these, cancer
induction may be a pathological consequence of elevated ROS
levels which lead to increased levels of oxidative DNA damage
which increases the risk of mutations that may lead to the
development of cancer2. Given the ubiquitous involvement of
oxidative damage in carcinogenesis, the Keap1–Nrf2–ARE path-
way has been widely regarded as a potential therapeutic target for
chemoprevention.
Various studies have revealed that Nrf2 plays a central role in
cancer chemoprevention by promoting the expression of detox-
iﬁcation enzymes and cytoprotective proteins. Inducers of Nrf2
function as chemopreventive agents by preventing carcinogens
from reaching their target, inhibiting parent molecules from
undergoing metabolic activation, or preventing carcinogens from
interacting with vital biomolecules such as DNA, RNA, and
proteins. Disruption of the Nrf2 gene leads to increased suscept-
ibility to environmental carcinogenesis by altering the expression
of detoxifying enzymes and leads to the loss of chemopreventive
efﬁcacy by inducers. Therefore, induction of the Nrf2–ARE has
been recognized as an important molecular and therapeutic target
for chemoprevention.
Despite its promising potential for chemoprevention in normal
and premalignant tissues, Nrf2 has also been shown to have a role
in tumor cell growth and survival in malignant cells51. High levels
of Nrf2 have been found in several types of human cancer cells,resulting from mutations in Keap1 or Nrf2 that result in consti-
tutive expression of up-regulated genes52,53. Nrf2 overexpression
appears to exert its protective role in both normal and cancer cells.
Studies show that elevated levels of Nrf2 can lead to increased
expression of detoxiﬁcation enzymes, cytoprotective proteins, and
transporters. This gives cancer cells an advantage by enhancing
cell proliferation and can cause resistance to chemotherapy51–55.
Recent studies have shown that inhibition of Nrf2 in malignant
cells suppresses tumor growth and enhances the efﬁcacy of
chemotherapy56,57. Therefore, Nrf2 could be targeted for the
treatment of cancer by either inducing activity for chemopreven-
tion or inhibiting activity in existing tumors.
4.2. Neurodegenerative diseases
The brain is highly susceptible to oxidative damage due to its high
lipid content, high oxygen consumption, and the high presence of
redox-active metals, including Cu and Fe capable of catalytic ROS
production. Neurodegenerative diseases share several pathological
features including the accumulation of aberrant protein aggregates
and mitochondrial dysfunction, excitotoxicity, and proteasomal
dysfunction58. Enhanced ROS production and oxidative damage
play the pivotal role in the onset and advancement of neurode-
generative diseases such as Alzheimer's disease (AD), Parkinson's
disease (PD)58. The protective effect of Nrf2 against oxidative
stress and neurotoxicity has been reported and the Keap1–Nrf2–
ARE pathway have been proposed and investigated as a potential
therapeutic target in AD and PD59,60. Activation of Nrf2 has been
investigated for its potential therapeutic applications in other
neurological disorders such as Huntington's disease, amyotrophic
lateral sclerosis (ALS or Lou Gehrig's disease), multiple sclerosis,
traumatic brain injury and cerebral hemorrhages3,58,61.
4.3. Diabetes and diabetic complications
Experimental evidence has established that oxidative stress is
involved in the pathogenesis of diabetes and the development of
diabetic complications, including diabetic cardiomyopathy and
nephropathy. Hyperglycemia has been shown to induce oxidative
stress due to an increase in glucose metabolism and, thus,
mitochondrial production of ROS62–64. The Nrf2–ARE pathway
has been shown to play an important role in the regulation of
energy metabolism, which has led to interest in the pathway as a
potential target for the prevention and treatment of metabolic
diseases such as diabetes. Nrf2 levels have also been shown to be
lower in pre-diabetic and diabetic patients as compared to patients
without diabetes, which suggests that diminished Nrf2 expression
is involved in the development of oxidative stress in diabetes65,66.
Induction of Nrf2–ARE regulated genes attenuates insulin resis-
tance and even inhibits the accumulation of fat67,68. The role of
Nrf2 in the regulation of metabolism and blood glucose levels has
generated interest in targeting the pathway for the prevention and
treatment of diabetes.
In addition to metabolic regulation and the pathogenesis of
diabetes, Nrf2 appears to have an important role in diabetic
complications. Oxidative stress is known to have a role in diabetic
complications, including diabetic cardiomyopathy and nephropa-
thy. Studies have indicated increased production of ROS in
diabetic cardiomyocytes. This suggests that high levels of glucose
induce ROS production and, thus, oxidative damage to the
vasculature that directly contributes to the evolution of diabetic
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protection against glucose-induced oxidative stress and diabetic
cardiomyopathy. Multiple studies have shown experimental evi-
dence that demonstrates the involvement of Nrf2 in diabetic
nephropathy. Streptozotocin (STZ) treated-Nrf2-null mice were
determined to be more susceptible to oxidative damage and renal
impairment than wild type mice62,69,70. The protective role of Nrf2
in diabetic nephropathy suggests that activation of Nrf2 could be
used to prevent or impede the advancement of the disease. For
example, bardoxolone methyl (CDDO-Me) is a potent activator of
Nrf2 and was clinically evaluated for the treatment of chronic
kidney disease in patients with type 2 diabetes71.
4.4. Chronic obstructive pulmonary disease (COPD) and other
respiratory diseases
The respiratory system can be particularly susceptible to oxidative
stress. Since the airways are the ﬁrst point of contact for inhaled
oxidants, the redox balance in the airway can be continuously and
repeatedly disturbed by the increased accumulation of oxi-
dants72,73. Pulmonary expression of Nrf2 is primarily found in
the epithelium and alveolar macrophages. The absence or deple-
tion of Nrf2 expression has been shown to aggravate lung toxicity
caused by multiple oxidative sources including cigarette smoke,
allergens, viral infections, bacterial endotoxins, hyperoxia, and
various environmental pollutants72. Several studies have also
revealed that Nrf2 deﬁciency is associated with a greater suscept-
ibility to COPD, emphysema, asthma, pulmonary ﬁbrosis, acute
respiratory distress syndrome and sepsis73–77. Therefore, activation
of Nrf2 in alveolar macrophages appears to be a promising
therapeutic target for the treatment of numerous respiratory
diseases.
4.5. Cardiovascular disease (CVD)
Oxidative stress has been implicated in a number of cardiovascular
diseases (CVDs) including atherosclerosis, hypertension, and
cardiomyopathy. Therefore, the role of Nrf2 in CVD and its
potential as a therapeutic target for the treatment of CVD has been
of recent interest. Nrf2 is ubiquitously expressed in the cardiovas-
cular system and plays a crucial role in maintaining cardiovascular
homeostasis via the induction of ARE-dependent genes78. Nrf2 has
been investigated as a therapeutic target for the treatment of
cardiomyopathy and atherosclerosis; however, the results of these
experiments have been inconclusive79. Although Nrf2 has shown
vascular protective effects and has been suggested as a potential
strategy for the treatment of atherosclerosis, several studies have
proposed that Nrf2 promotes the pathogenesis of atherosclerosis
through a different mechanism80,81. Therefore, the potential pro-
atherosclerosic effects of Nrf2 activation should be considered
when designing Nrf2-targeted therapies for the treatment of CVD
and other diseases.
4.6. Other diseases and conditions involving the Nrf2-ARE
pathway
In addition to the diseases described above, the role of Nrf2 and its
therapeutic potential have been investigated in numerous other
diseases and health issues. The role of Nrf2 in gastrointestinal
diseases, such as ulcerative colitis and chronic gastritis, has been
investigated and appeared to strongly inhibit pro-inﬂammatorysignaling associated with these conditions82–85. The involvement
of Nrf2 in the pathogenesis and treatment of liver disease and
hepatotoxicity has been extensively investigated. Nrf2 was found
to be crucial in combatting hepatotoxicity and liver injury86–90.
Nrf2 also regulates the innate immune response and modulation of
the Nrf2 pathway has been involved in diminishing various
immune and inﬂammatory responses associated with infec-
tions91–93, autoimmune diseases94–96, and other innate immune
responses97–99. The vast number of diseases and biological
mechanisms that involve the Keap1–Nrf2–ARE clearly indicate
its importance. The potential applications make the pathway a very
interesting and promising target for drug design.5. Direct inhibition of Keap1–Nrf2 protein–protein
interaction (PPI)
The large amount of evidence indicating the importance of Nrf2
activation to human health has prompted interest in the discovery
of small molecule and peptide activators of the Keap1–Nrf2–ARE
pathway. Numerous natural (e.g., curcumin, sulforaphane, and
isothiocyanate) and synthetic (e.g., bardoxolone methyl, oltipraz
and Tecﬁdera™) small molecules that induce ARE-dependent gene
expression have been investigated for their medicinal and ther-
apeutic properties. However, most of these Nrf2 activators
currently known are indirect inhibitors of the Keap1–Nrf2 inter-
action. The indirect inhibitors are electrophilic species or are
metabolically transformed in vivo to become electrophilic, and
subsequently react with the sulfhydryl groups of cysteine residues
in Keap1 by oxidation or alkylation100,101. Indirect inhibitors and
their molecular mechanisms of action have been reviewed
previously7. The electrophilicity of indirect inhibitors poses a
problem. Their lack of speciﬁcity and selectivity increases the risk
of “off-target” toxic effects due to their ability to react with the
cysteine residues of other enzymes and proteins. Therefore, direct
inhibition of the Keap1–Nrf2 PPI has recently become an
appealing strategy for activation of Nrf2. The discovery of non-
reactive direct small molecule inhibitors of the Keap1–Nrf2
pathway appears to be the most promising strategy due to the
diminished possibility of toxic effects, as compared with indirect
inhibitors, and increased stability and bioavailability, as compared
with peptide inhibitors102,103.
5.1. Screening assays for the discovery of small molecule direct
inhibitors of Keap1–Nrf2 PPI
Several different assays have been developed for the screening and
identiﬁcation of small molecule inhibitors of the Keap1–Nrf2 PPI.
These include surface plasmon resonance (SPR)-based solution
competition assay, ﬂuorescence polarization (FP) assay and the
cell-based Neh2-luciferase assay.
5.1.1. SPR-based solution competition assay
The SPR-based solution competition assay selectively screens for
Nrf2 activators that directly inhibit Keap1–Nrf2 interaction7,104. In
this assay, the Kelch domain of Keap1 is allowed to ﬂow in
solution over an SPR sensor chip with the 16mer Nrf2 peptide
immobilized on the sensor chip surface. The optimal immobiliza-
tion method is the use of a biotin-labeled 16mer Nrf2 peptide
immobilized as the ligand on a streptavidin sensor chip. These
conditions provided sensitive and stable surfaces for both kinetic
analysis of the Keap1–Nrf2 PPI and detection of free Keap1 Kelch
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method was used to determine the minimal Nrf2 peptide sequence
required to bind Keap1 Kelch domain104. The advantage of this
assay is that it allows for the measurement of direct inhibition of
Keap1–Nrf2 interaction. However, the limited throughput of the
SPR-based assay prevents it from being used as the primary assay
in high-throughput applications7,104.5.1.2. Fluorescence polarization (FP) assay
FP is a powerful tool used to study the interactions between
biomolecules in solution. FP competition assays can be used to
screen for small molecules that inhibit ligand-receptor interactions105.
We previously reported the development of an FP assay that can be
used for high-throughput screening of large chemical libraries in an
effort to identify small molecule inhibitors of Keap1–Nrf2 interac-
tion106. Fluorescently-labeled-Nrf2 peptides containing the ETGE
motif were designed and synthesized as tracers to detect direct
inhibitors of Keap1–Nrf2 interaction. Flurescein isothiocyanate
(FITC)-labeled Nrf2 9mer peptide amide was determined to be the
optimal tracer and was used in our FP assay. We have successfully
used this assay in the high-throughput screening (HTS) of the NIH
MLPCN small molecule library to discover small molecule inhibitors
of Keap1–Nrf2 interaction7,102,106.5.1.3. Cell-based Neh2-luciferase assay
In the cell-based Neh2-luciferase assay, a Neh2-luciferase reporter
system is constructed with the Neh2 domain of Nrf2 fused to a
luciferase gene as a tool to monitor Nrf2 activation in real time107.
The overexpressed Neh2-luciferase fusion protein competes with
endogenous Nrf2 for Keap1 binding and subsequent ubiquitination
and degradation. Nrf2 activators disrupt the Neh2-luc-Keap1-Cul3
complex and, thus, the Neh2-lucisferase protein is not degraded.
The increase in luciferase activity serves as a direct measure of the
ability of a compound to disrupt the Keap1–Nrf2 interaction. The
advantage of this assay is that there is an immediate response upon
the addition of Nrf2 activators, which allows for differentiation of
Nrf2 activators by monitoring their kinetics of reporter activation.
This system is suitable for HTS with Z'-values of 40.77,107.Table 1 The inhibition of the Keap1–Nrf2 interaction by Nrf2 pept
Entry Peptide name Peptide sequence
1 7mer Nrf2 H-EETGEFL-OH
2 8mer Nrf2 H-DEETGEFL-OH
3 8mer Nrf2-NH2 H-DEETGEFL-NH2
4 9mer Nrf2 H-LDEETGEFL-OH
5 9mer Nrf2-NH2 H-LDEETGEFL-NH2
6 Ac-9mer Nrf2 Ac-LDEETGEFL-OH
7 Ac-9mer Nrf2-NH2 Ac-LDEETGEFL-NH2
8 10mer Nrf2 H-QLDEETGEFL-OH
9 11mer Nrf2 H-LQLDEETGEFL-OH
10 12mer Nrf2 H-QLQLDEETGEFL-OH
11 14mer Nrf2 H-FAQLQLDEETGEFL-OH
12 16mer Nrf2 H-AFFAQLQLDEETGEFL-OH
aResults from the SPR assay104.
bResults from the FP assay106.5.2. Peptide inhibitors and Nrf2-based peptide probes
The elucidation of the structure of the Keap1–Nrf2 binding interaction
provided important insight into the development of peptide inhibitors
of the interaction. Speciﬁc amino acids that are critical for Keap1–
Nrf2 binding were ﬁrst determined using extensive alanine-scan
mutagenesis of the Keap1 protein108. Replacement of the residues
Tyr334, Asn382, His436, Tyr525, and Tyr572 with alanine residues
considerably disrupted the ability of Keap1 to bind to Nrf2. It was
also determined that the Phe478 residue is not required for Keap1–Nrf2
binding, but it is required for suppression of Nrf2-dependent gene
expression. When Phe478 was replaced with an alanine residue, the
mutant was unable to direct Nrf2 ubiquitination. Additionally, there
are three arginine residues that were determined to be critical for
Keap1–Nrf2 binding: Arg380, Arg415 and Arg483. By understanding
the structure Keap1–Nrf2 binding interface, various peptides have
been designed to either simply inhibit the interaction or serve as a
probe to gauge the activity of small molecule inhibitors in screening
assays108.5.2.1. Peptide inhibitors of Keap1–Nrf2 PPI
Our laboratory designed a series of truncated peptides based on the
ETGE motif of Nrf2 and evaluated them as direct inhibitors of the
Keap1–Nrf2 PPI using the SPR assay and the FP assay we
developed104,106. The afﬁnity of the non-acetylated Nrf2 peptides
increases with increasing peptide length as shown in
Table 1104,106. The 7mer peptide (entry 1, Table 1) was totally
inactive and the 8mer (entry 2, Table 1) was only weakly active,
while the 9mer (entry 4, Table 1) was shown to be signiﬁcantly
more active with a Kd of 350 nmol/L in the SPR assay and IC50 of
3.48 μmol/L in FP assay corresponding to an Ki of 865 nmol/L.
Longer Nrf2 peptides (10mer to 16mer peptides (entries 8–12,
Table 1)) are much more active with Kd ranging from 22 to
31 nmol/L and IC50 values from 0.163 to 0.298 μmol/L. We
observed the N-terminal acetylation of 9mer Nrf2 peptide sig-
niﬁcantly increased the binding afﬁnity to Keap1 Kelch domain to
a level that is similar to the binding afﬁnities of the longer Nrf2
peptides while C-terminal amidation of 9mer Nrf2 peptide had
little effect104,106. Based on these studies, we concluded that
minimal binding sequence of Nrf2 ETGE motif to Keap1 Kelch
domain is the 9mer sequence of LDEETGEFL104,106.ides as determined using SPR and FP assay.
Ksolutiond (nmol/L)
a IC50 (μmol/L)b Ki (nmol/L)b
441000 44100 —
441000 21.7720.1 7010
— 30.5722.7 9870
352 3.4870.92 865
355 3.5772.20 1140
23.1 0.19470.049 47.4
21.4 0.19670.032 48.1
27.3 0.27270.026 72.7
31.3 0.29870.033 81.1
23.8 0.24970.022 65.2
22.5 0.24370.020 63.3
23.9 0.16370.011 37.4
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inhibitors of Keap1–Nrf2 PPI based on the ETGE or DLG motif of
the Neh2 domain of Nrf2 using peptide phage display library and
investigated their ability to bind the Kelch domain of human Keap1
using an FP assay109. They determined that the minimal sequence
required for binding between the ETGE motif and the Kelch domain
is the seven-amino-acid sequence Ac-DEETGEF-OH and that the
optimal sequence was Ac-DPETGEL-OH. They also determined
that the minimal sequence required for binding between the DLG
motif and the Kelch domain is Ac-WRGDIDL-OH (Fig. 5)109. In a
later study, they modiﬁed the peptides by replacing the acetyl
groups at the N-terminus with benzoyl or stearoyl groups to increase
the lipophilicity of the molecules and assess their effect on binding
with the Kelch domain using an FP assay. They found that the
sequence stearoyl (St)-DPETGEL-OH demonstrated potent activity
(IC50¼22 nmol/L), and promoted expression of Nrf2-dependent
gene expression in a cell-based assay110.
In another study of Keap1–Nrf2 peptide inhibitors, Searcey and
co-workers synthesized a series of TAT-conjugated ETGE pep-
tides that target the interaction. They evaluated Nrf2 activation by
measuring the expression of the downstream target gene heme
oxygenase–1 (HO-1). They found that only the TAT-ETGE-14mer
(TAT-14: YGRKKRRQRRRLDEETGEFLPIQ) was able to
induce HO-1 expression in a time and dose dependent manner111.
5.2.2. Fluorescently labeled Nrf2 peptide probe optimization
The need for an assay adaptable to HTS of large chemical libraries to
aid in the identiﬁcation and design of small molecule inhibitors of
Keap1–Nrf2 PPI lead us to develop the FP assay described above106.
Fluorescently-labeled Nrf2-peptides containing the ETGE motif were
designed and synthesized as probes to detect the direct inhibition of
the Keap1–Nrf2 PPI. In our effort to optimize the ﬂuorescent Nrf2
peptide probe in terms of Keap1 Kelch domain–binding afﬁnity and
the dynamic range of the assay, we prepared and evaluated a series of
FITC-labeled 8–16mer Nrf2. As shown in Table 2106, the FITC-
labeled 9mer Nrf2 peptide demonstrated a binding afﬁnity compar-
able to the longer FITC-labeled Nrf2 peptides (entry 3 vs. entries 5–9,
Table 2), which suggests that most of the bonding interactions
between the Kelch domain and Nrf2 reside within the 9mer peptide
sequence (LDEETGEFL). Thus, the binding afﬁnity was not
signiﬁcantly affected by peptide length as long as the peptide
contains the nine amino acids in the DxETGE motif. In addition,
the FITC-labeled 9mer Nrf2 peptide amide (entry 4, Table 2)
demonstrated the highest dynamic range among the peptides tested.Table 2 FITC-labeled Nrf2 peptides of different length (8 mer to 1
Entry Peptide name Peptide sequence
1 FITC-8mer Nrf2 FITC-DEETGEFL-OH
2 FITC-8mer Nrf2-NH2 FITC-DEETGEFL-NH2
3 FITC-9mer Nrf2 FITC-LDEETGEFL-OH
4 FITC-9mer Nrf2-NH2 FITC-LDEETGEFL-NH2
5 FITC-10mer Nrf2 FITC-QLDEETGEFL-OH
6 FITC-11mer Nrf2 FITC-LQLDEETGEFL-O
7 FITC-12mer Nrf2 FITC-QLQLDEETGEFL
8 FITC-14mer Nrf2 FITC-FAQLQLDEETGE
9 FITC-16mer Nrf2 FITC-AFFAQLQLDEET
aAnisotropy measurements were performed using FP assay106.
bThe Kd of the FITC-labeled 8mer Nrf2 peptides were assessed using th
cBecause of low binding afﬁnity, the higher end of the dynamic range cTherefore, the FITC-labeled 9mer Nrf2 peptide amide is the optimal
sequence and has been used as our probe in our FP assay7,106.
5.3. Small molecule direct inhibitors of Keap1–Nrf2 PPI
As stated earlier, the vast majority of inhibitors of Keap1–Nrf2 PPI
is electrophilic species that work by covalent modiﬁcation of the
cysteine residues in Keap1. Recently, several small molecule direct
inhibitors of Keap1–Nrf2 PPI through non-covalent binding to the
Keap1 Kelch domain have been reported102,103,112–114. We ﬁrst
reported in 2013 the discovery of small molecule direct inhibitors
of the Keap1–Nrf2 PPI102. The FP assay106 that we developed and
reported in 2012 was successfully used to screen the MLPCN
library of 337,116 compounds (PubChem Assay ID: 504523,
504540). The primary screen generated 489 hits at 10 μmol/L,
which was reduced to 460 hits after excluding ﬂuorescent
compounds. These 460 hits were subjected to conﬁrmation assays
using the eight-point dose-response FP assay and a thermal shift
secondary assay, generating 8 conﬁrmed hits. From these eight
hits, hit 1 (LH601) was the most promising, with an IC50 of
3 μmol/L in the FP assay and a Kd of 1.6–1.9 μmol/L in our SPR
assay102. In addition, there are no chemically reactive functional
groups present in LH601, therefore it is not expected to modify the
sulfhydryl groups of cysteine residues in Keap1 or other proteins.
LH601 has three chiral centers and four possible stereoisomers.
We separated the four isomers (LH601A–D) using a combination
of ﬂash silica gel chromatography and chiral HPLC puriﬁcation;
we then compared their Keap1 Kelch domain–binding activity
using our SPR and FP assays. It was found that LH601A is the
most active stereoisomer, which is about 100 times more potent
than its corresponding enantiomer LH601B while their diaster-
eomers LH601C&D are inactive. The stereospeciﬁc binding
activity of LH601 isomers made us more conﬁdent about the true
binding of LH601A to Keap1 Kelch domain. X-ray crystal-
lography was then used to assign the absolute stereochemistry of
LH601 isomers; the active stereoisomer LH601A was determined
to be of (S,R,S)-conﬁguration (1)102. We also synthesized a
number of analogs to determine the structure-activity relationships
of LH601A. Preliminary SAR studies provided the following
conclusions as shown in Fig. 6: (i) Keap1-binding activity
resides primarily in one stereoisomer of (S,R,S)-conﬁguration;
(ii) acid functionality on the cyclohexane ring is required for
optimal activity; (iii) a one-carbon linker between the tetrahydroi-
soquinoline (THIQ) and phthalimido group is optimal; (iv) one of6 mer): their binding afﬁnities and dynamic rangea.
Kd (nmol/L) Dynamic range (ΔmA)
750b –c
1000b –c
65.179.7 97.3
25.6710.8 109.8
30.176.1 73.5
H 47.777.4 96.3
-OH 44.5712.9 70.6
FL-OH 61.9716.5 64.2
GEFL-OH 28.775.7 80.1
e anisotropy of the fully bound FITC-9mer Nrf2 peptide.
ould not be determined.
Figure 5 Summary of structure–activity relationship data for the DLG motif (residues 24–30; blue) and the ETGE motif (residues 76–83; red).
Figure 6 Structure–activity relationships around LH601A (1)102.
The activity noted was based on the solution competition SPR assay.
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lactam that retains strong binding afﬁnity to Keap1 Kelch domain.
After conﬁrming the Keap1-binding activity of LH601A in our
FP and SPR assays, we determined its cellular activity in two cell-
based functional assays102. In the CellSensors ARE-bla HepG2
cell line where ARE controls the expression of β-lactamase,
LH601A was found induce ARE-controlled genes with an EC50
of 18 μmol/L as compared to 4100 μmol/L for its enantiomer
LH601B and its diastereomers LH601C/D. In the PathHunters
U2OS Keap1–Nrf2 functional assay that uses β-galactosidase-
based enzyme fragment complementation technology and lumi-
nescence for the detection of Nrf2 nuclear translocation, LH601A
promoted the nuclear translocation of Nrf2 with a similar EC50 of
12 μmol/L. All these data indicate that LH601A is cell-permeable
and is capable of inhibiting the Keap1–Nrf2 interaction, leading to
the dissociation of Nrf2 from Keap1 in the cytosol, its subsequent
translocation to the nucleus, and the upregulation of ARE-
controlled genes.Jnoff and colleagues113 at UCB Pharma recently conﬁrmed
most of our earlier ﬁndings and provided X-ray co-crystal structure
evidence that LH601A binds to the Nrf2 binding site on the Keap1
Kelch domain. The cocrystal structures of Keap1 Kelch domain
with LH601A and its analogs provide further conﬁrmation of the
stereochemistry of the active isomer LH601A and the nature of its
direct binding interaction to Keap1 Kelch domain. Several analogs
of LH601A were synthesized and evaluated by UCB scientists
leading to a more potent Keap1 binder, compound 4 (Fig. 7),
where one of the phthalimide carbonyl was reduced to form the
lactam and an additional methyl group was introduced at the 5
position of THIQ. Compound 4 is 3-fold more potent than 1 as an
inhibitor of Keap1–Nrf2 PPI in the FP assay. It was suggested that
the methyl group in compound 4 likely acts as a "lipophilic plug"
providing a good shape ﬁt toward the pore of the Kelch domain
resulting in the increase in potency as compared to 1113.
Silvian and colleagues114 at Biogen used a high throughput
homogeneous confocal ﬂuorescence anisotropy assay to screen the
lead discovery library of 267,551 compounds from Evotech plus
1911 compounds selected from a virtual screening and identiﬁed
two compounds as inhibitors of Keap1–Nrf2 PPI: the
benzenesulfonyl-pyrimidone 2 and the N-phenyl-benzenesulfona-
mide 3. Compound 2 was found to have an IC50 value of
118 μmol/L while 3 was found to have an IC50 of 2.7 μmol/L
in the confocal FP assay. Using an ARE-driven luciferase
reporter assay, 3 was shown to increase the levels of both Nrf2
and one of Nrf2 target genes NQO1 at 100 mol/L. Native mass
spectrometry (NMR) and X-ray crystallography were used to
Figure 7 Structures of direct inhibitors of Keap1–Nrf2 PPI that have recently been reported.
Dhulﬁqar Ali Abed et al.294conﬁrm that 3 binds speciﬁcally in the cavity of the Keap1 Kelch
domain114.
You and coworkers112 used virtual screening of the Specs
database and identiﬁed compound 7 as a small molecule inhibitor
of Keap1–Nrf2 PPI. Based on the crystal structure of the
interaction between the ETGE and DLG motifs of Nrf2 and the
Kelch domain of Keap1, they found that a negative ionizable
center should be included in Keap1–Nrf2 PPI inhibitors. Before
screening the library, 90% of the compounds in the Specs database
were excluded because they possessed a formal charge of more
than 1. This reduced the number of compounds from 251,774 to
21,119. The virtual screening of the 21,119 compounds leads to 17
virtual hits that were experimentally evaluated in the FP assay to
identify the small molecule inhibitors of the Keap1–Nrf2 PPI.
Compound 7 with a symmetrical structure containing two benzoic
acids at the ends and a carbodihydrazide in the middle was
reported to have an IC50 of 9.80 μmol/L in the FP assay but
relatively low ARE-inducing activity in a cell-based assay due to
its poor cell permeability112.
In a more recent study by You, Sun and coworkers103, a potent
direct inhibitor 6 of the Keap1–Nrf2 PPI was derived from the
Biogen inhibitor 3 as shown in Fig. 7. Compound 6 was reported
to have an IC50 of 28.6 nmol/L and a Kd of 3.59 nmol/L in the FP
assay. Studies on the molecular binding determinants and mole-
cular dynamics (MD) simulations of Keap1–Nrf2 PPI suggested
that the incorporation of two acetic acid side chains to 3 would
provide favorable binding interactions with the Keap1 Kelch
domain. The activity of 6 was also demonstrated thro-
ugh the cell-based ARE-luciferase reporter assay and the
qRT-PCR103.
In another study reported by Sham, Xing and coworkers115,
rapid structure-based virtual screening and hit-based substructure
search were utilized to identify small molecules that disrupt
Keap1–Nrf2 PPI. The noncovalent inhibitor 5 was reported to
have comparable Keap1 binding afﬁnity to 3 in an FP assay, but is
3-times more active than compound 3 in a cell-based assay115.
Another interesting but simple compound (8) containing a
furanyloxadiazole linked to a phenoxyacetic acid, was reported
to be a direct inhibitor of Keap1–Nrf2 PPI in a Japanese patent
application116. Two co-crystal structures of Keap1 Kelch domain
with 8 were deposited to PDB databank (PDB ID: 3VNG, 3VNH)but neither the binding afﬁnity of 8 to Keap1 Kelch domain nor
any cellular ARE-inducing activity have been reported.5.4. X-ray co-crystal structures of Keap1 Kelch domain with
small molecule direct inhibitors of Keap1–Nrf2 PPI
The 3-D structures of the human and mouse Keap1 Kelch domain
with and without Nrf2-derived peptides were determined by X-ray
crystallography31,108,117. The crystal structure of the human Keapl
Kelch domain was determined at 1.35 Å resolution31 while the
complex of human Keap1 Kelch domain with the 16mer Nrf2
peptide bound was reported at 1.5 Å resolution (PDB ID:
2FLU)108,117. Furthermore, the structures of the mouse Kelch
domain of Keap1 with and without Nrf2 peptide were also
determined by X-ray crystallography (PDB ID: 1X2J and
1X2R). The human and mouse Keap1 are very similar in sequence
with sequence identity of 94% overall and 97% in the Kelch
domain. Both cocrystal structures of the human and mouse Keap1
Kelch domain–Nrf2 peptide complexes overlay very well with
each other and the apo structure of human Keap1 Kelch domain.
After alignment of the three crystal structures, our analysis
indicates that the RMSDs for the Cα atoms range between 0.40
and 0.48 Å and for all atoms between 0.87 and 0.95 A ̊ over the 285
Keap1 Kelch domain residues. They all show that the Kelch
domain folds up into a highly symmetric 6-bladed β-propeller
structure with each blade consisting of 44–51 amino acids
(Fig. 8A). The 16mer Nrf2-derived peptide has two antiparallel
β-strands connected by a turn region that has two tight overlapping
type-1 β turns (residues 77–80 and 78–81). The Nrf2 peptide binds
to the top face of the β-propeller with all six blades contributing to
the complex formation (Fig. 8A and B). Side chains from six
residues in Keap1 (Ser363, Asn382, Arg380, Arg415, Arg483 and
Ser508) participate in H-bond interactions to the carboxylate
oxygen atoms from E79 and E82 in the Nrf2 peptide (Fig. 8C)
and several Keap1 residues are involved in H-bond interactions to
the peptide backbone and in van der Waals interactions between
the Kelch domain and the Nrf2 peptide (Fig. 8B). Another
interesting feature of the Keap1 Kelch domain with relevance to
peptide-binding site is the positively charged region which is
primarily due to the highly conserved Arg residues. Only the side
Figure 8 Structures of the Kelch domain of human Keap1 bound to an Nrf2 peptide. (A) A top-down view showing the six-bladed β-propeller
structure in red ribbon and the peptide as a yellow tube. Each blade of the β-propeller is numbered I–VI. Both the N- and C-termini of the domain
are located in blade I and are labeled N and C, respectively. The four β-strands found in each blade are designated A–D as shown in white font on
blade VI. (B) A surface representation of the Kelch propeller (gray) and peptide (yellow tube). Selected residues are shown in blue (basic), orange
(polar) and green (apolar). (C) Charge–charge and H-bonding interactions between the side chain atoms of the Nrf2 peptide and residues in the
Kelch domain. Not shown are 5 H-bond interactions between the peptide backbone atoms and residues in the Kelch domain (reproduced with
permission from reference
108
).
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interactions with the binding site. The carboxylate group of
peptide E79 interacts with the side chains of Ser508, Arg415, and
Arg483 while the carboxylate group atoms of peptide E82 interacts
with the side chains of Ser363, Asn382, and Arg380 (Fig. 8C). These
structure details revealed in the high resolution (1.5 Å) co-crystal
structure of the human Keap1 Kelch domain-Nrf2 peptide complex
suggest that inhibitors that interfere with the Keap1–Nrf2 PPI can
derive their inhibition by binding Keap1 Kelch domain at the site
where Nrf2 peptide is binding.
Moreover, several structural and functional evidences substan-
tially support the concept that the DxETGE motif is the principal
Keap1 binding site in Nrf2 peptide. The lysine-rich residues in
Nrf2 required for ubiquitination are located at a distance of 10–30
amino acids on the DxETGE N-terminal side 21, and these
residues would be positioned for ubiquitin transfer upon binding
of Nrf2 to Keap1 via the DxETGE motif. The second low-afﬁnity
Keap1 binding site in Nrf2 containing the LxxQDxDLG sequence
located at a distance of approximately 50 amino acids on the N-
terminal side of the DxETGE motif.
Based on the cocrystal structure of Keap1 Kelch domain with
the 16mer Nrf2 peptide (PDB ID: 2FLU), we docked LH-601A to
the Nrf2 peptide binding site in Keap1 Kelch domain. The strength
of binding between LH-601A and Keap1 increases by interactions
between THIQ and Arg415 (π-cation), phthalimido and Arg380 (π-
cation), and the hydrogen-bonding interactions which were
observed between Keap1 and Nrf2 peptide. Jnoff and colleagues
also docked LH601A to the Nrf2 peptide binding site in Keap1
Kelch domain based on the cocrystal structure of Keap1 Kelch
domain with the 16mer Nrf2 peptide (PDB ID: 2FLU) and the
crystal structure of Kelch domain of human Keap1 PDB ID:
(1ZGK)113. In their top pose, the LH-601A cyclohexyl group
posits in a similar pocket to our docked pose while the remainder
of LH-601A forming completely different interaction patterns. In
their co-crystal structure of a mutant Keap1 Kelch domain with
LH601A (PDB ID: 4L7B)113, the aromatic ring of the THIQ group
oriented into the central pore, while the phthalimide
and cyclohexane carboxylic acid moieties extending outward.Regarding the phthalimide group, the ﬁrst carbonyl group is
hydrogen-bonded to Ser602, the second carbonyl group is
hydrogen-bonded to Ser555 through water molecule, and ﬁnally
the phenyl ring interacts with Tyr572 through a π-stacking. The
cyclohexane carboxylic acid group is hydrogen-bonded to both
Arg415 and Asn414.
Silvian and colleagues114 from Biogen cocrystallized com-
pounds 2 and 3 mentioned above with Keap1 Kelch domain.
Compound 2 (PDB ID: 4IN4) co-crystallized to 2.6 Å resolution
with two molecules of 2 binding side-by-side in each central cavity
of Keap1 Kelch domain (i.e. 2 binds to the Keap1 Kelch domain
protein in a 2:1 stoichiometry (Fig. 9B)). Both electrostatic and
hydrophobic interactions are involved between compound 2 and
the Keap1 Kelch domain protein. Three serine residues (Ser508,
Ser555 and Ser602) and two arginines (Arg415 and Arg483) form H-
bonds with the two molecules of 2 while Tyr525 and Phe477
residues form π-π stacking interactions with two molecules and
there exists hydrophobic interaction between the CF3 group in one
molecule (A) of 2 and the meta-dimethylphenyl group in the other
molecule (B) of 2. There seems to be no cooperative interaction
between the two molecules of 2 in each binding site with Hill
coefﬁcient close to 1.0. The more potent compound 3 (PDB ID:
4IQK) co-crystallized to 2.0 Å resolution where 3 binds to the
Keap1 Kelch domain protein in a 1:1 stoichiometry. Compound 3
interacted through four π-π stacking interactions with Keap1 side
chains of residues Tyr334, Tyr525, Tyr572 and Arg415. The electron-
rich naphthalene ring stacks with Arg415 and the second naphtha-
lene ring inserted deep into the polar hole of the central cavity.
Furthermore, Serine residues, Ser508 and Ser602, form H-bond
interactions with compound 3114.6. Conclusions
The Keap1–Nrf2–ARE pathway is a critical antioxidant defense
mechanism that protects cells from oxidative stress. Since oxida-
tive stress has been implicated in numerous human diseases and
conditions, the Keap1–Nrf2–ARE pathway has been become an
Figure 9 The interactions observed in X-ray co-crystal structures of Keap1 Kelch domain with small molecule direct inhibitors of Keap1–Nrf2
PPI: (A) 1 or (B) 2 or (C) 3. Ionic interactions are indicated with red dotted lines and hydrophobic interactions are indicated with blue dotted
double sided arrows. There are two ligands occupying the binding site in the co-crystal structure of Keap1 Kelch domain with 2. (A was
reproduced with permission from reference113).
Dhulﬁqar Ali Abed et al.296important cellular target for the development of potential ther-
apeutic and preventive agents for a number of diseases and
conditions. Nrf2 is the master transcription factor of ARE-
dependent genes and Keap1 is the major negative regulator of
Nrf2. Most ARE inducers known are indirect inhibitors of Keap1–
Nrf2 PPI that are electrophilic species acting by modifying the
sulfhydryl groups of Keap1's cysteine residues. However, the
electrophilicity of indirect inhibitors is problematic due to the
potential for "off-target" reactions with cysteine residues of other
important cellular proteins. To circumvent the potential toxic side
effects caused by these "off-target" reactions, several direct
inhibitors of Keap1–Nrf2 PPI have been developed. These direct
inhibitors function by inhibiting the Keap1–Nrf2 PPI via a non-
covalent mechanism and could potentially be developed into
effective therapeutic or preventive agents, representing a novel
therapeutic strategy for the treatment and/or prevention of a variety
of diseases and conditions.Acknowledgments
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